Grundlagen zur Nachbehandlung einer Denosumab -Therapie.

The guideline "Fundamentals of post-treatment after Denosumab therapy" addresses the post-treatment after Denosumab therapy for the treatment of osteoporosis. Denosumab therapy can lead to an increased risk of bone density loss and vertebral fractures. Studies have shown that the risk of vertebral fractures persists even after discontinuing the therapy. Post-treatment with bisphosphonates, especially Zoledronic acid, can maintain bone density and prevent fractures. The correct time interval between discontinuing Denosumab therapy and starting post-treatment is crucial. It is recommended to start treatment with Zoledronic acid no later than six months after the last administration of Denosumab and to regularly monitor bone markers and bone density measurements. Close collaboration with experienced osteoporosis specialists is recommended. [Extracted from the article]